Shares of Tiziana Life Sciences PLC (LON:TILS – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 58.50 ($0.73) and traded as low as GBX 45 ($0.56). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.73), with a volume of 297,127 shares trading hands.
Tiziana Life Sciences Stock Performance
The company has a current ratio of 6.54, a quick ratio of 6.41 and a debt-to-equity ratio of 2.36. The business has a 50 day moving average of GBX 58.50 and a 200-day moving average of GBX 58.50. The stock has a market cap of £113.85 million and a PE ratio of -3.59.
About Tiziana Life Sciences
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
See Also
- Five stocks we like better than Tiziana Life Sciences
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Comprehensive PepsiCo Stock Analysis
- Are Penny Stocks a Good Fit for Your Portfolio?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Insider Buying Explained: What Investors Need to Know
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.